Abbott Laboratories

Abbott plans to separate its nutrition business — which includes brands such as Similac, PediaSure, Pedialyte, Glucerna and Ensure — into an independent, publicly listed company. The segment most recently generated about $8.5 billion in revenue and employs roughly 16,000 people. The spinoff is expected to be completed by the end of 2027; one‑time costs will be incurred before the separation, but their amount has not been disclosed. Abbott does not expect the planned transaction to affect its 2026 earnings guidance or its outlook for 2027; the stock fell in NYSE trading. » Mere på finanzen.net

Abbott Laboratories agreed to a $385 million settlement over False Claims Act allegations related to baby food from its Sturgis and Casa Grande plants. About $348.7 million will go to the federal government and $36.3 million to states for Medicaid claims. The settlement contains no finding of fault and ends the years‑long investigation, which helped lift the stock despite a weak market; the next quarterly report is due in mid‑October. » Mere på de.investing.com

Abbott agreed to a $385 million settlement with federal and state authorities and civil plaintiffs over contamination issues at its Sturgis, Michigan, baby formula plant that triggered a national shortage in early 2022. The Justice Department criticized persistent unsanitary conditions and temporary fixes at the facility but has closed its criminal investigation. Abbott said the settlement resolves the investigations without admission of fault and noted unopened distributed formula never tested positive for Cronobacter sakazakii; the CDC found no definitive link to clinical cases. The agreementaims to address allegations of violations of federal health and safety requirements and to hold the company financially accountable. » Mere på forbes.com

Abbott has received FDA approval for the TactiFlex Duo, Sensor Enabled ablation catheter for the treatment of atrial fibrillation. The catheter combines pulsed field ablation and radiofrequency energy in a single device, allowing physicians to use one or both energy modalities during minimally invasive procedures. The approval is based on the FlexPulse IDE study, which demonstrated safety and effectiveness in paroxysmal atrial fibrillation; the device is compatible with the EnSite X EP system. Abbott will begin initial uses and a nationwide rollout in the coming weeks; this is the fifth major electrophysiology approval for the company within a year. » Mere på de.investing.com

Abbott Laboratories, a Dividend King with 54 consecutive years of raises, reported Q2 sales of $12.6 billion and raised its full-year adjusted EPS guidance, supporting a forward dividend yield of about 2.3% and a payout ratio near 46%. Management expects faster sales and earnings in H2 2026, driven by medical devices launches and the recent $21 billion Exact Sciences acquisition that is expanding growth in cancer diagnostics. Strong cash flow, ongoing share returns and analyst optimism underpin the view that Abbott can sustain and potentially raise dividends through a market downturn. » Mere på finance.yahoo.com